tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inovio Pharmaceuticals’ Glioblastoma Study Update: What Investors Need to Know

Inovio Pharmaceuticals’ Glioblastoma Study Update: What Investors Need to Know

Inovio Pharmaceuticals ((INO)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

Inovio Pharmaceuticals is conducting a Phase 1/2 clinical trial titled An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM). The study aims to evaluate the safety, immunogenicity, and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab, radiation, and chemotherapy in patients with newly-diagnosed glioblastoma, a highly aggressive brain cancer.

The interventions being tested include INO-5401 and INO-9012, both delivered by electroporation, and cemiplimab, an antibody targeting the PD-1 protein. These treatments are designed to enhance the immune response against glioblastoma cells.

The study follows a non-randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. It includes two cohorts based on the methylation status of the MGMT promoter in tumor cells, which may influence treatment response.

The trial began on May 31, 2018, with its last update submitted on July 2, 2025. These dates are crucial as they provide a timeline for the study’s progress and potential data availability.

The update from this study could influence Inovio’s stock performance and investor sentiment, especially if results show promising efficacy. The competitive landscape includes other companies developing treatments for glioblastoma, which may also impact market dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1